NovoCure (NVCR) Treasury Shares (2017 - 2026)

NovoCure has disclosed Treasury Shares across 10 years of filings, most recently posting $12.6 million for Q1 2026.

• Treasury Shares for Q1 2026 came in at $12.6 million, down 9.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.6 million (down 9.21% YoY), and the FY2025 annual result was $13.1 million, up 8.85% from the prior year.
• Treasury Shares came in at $12.6 million for Q1 2026 at NovoCure, down from $13.1 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $13.9 million in Q1 2025 to a low of $5.0 million in Q1 2022.
• The 5-year median for Treasury Shares is $12.1 million (2024), against an average of $9.6 million.
• Across the five-year window, Treasury Shares surged 142.87% in 2024 and retreated 9.21% in 2026, its largest moves.
• NovoCure's Treasury Shares stood at $5.4 million in 2022, then climbed by 8.1% to $5.8 million in 2023, then jumped by 107.58% to $12.1 million in 2024, then increased by 8.85% to $13.1 million in 2025, then dropped by 3.86% to $12.6 million in 2026.
• The last three Treasury Shares figures came in at $12.6 million (Q1 2026), $13.1 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.